Reduction in GM2 Ganglioside Content in the CNS of Treated SD Mice
GM2 ganglioside was quantified in cerebrum, cerebellum, brainstem, and spinal cord of SD mice in the high dose cohorts at 150 days of age or humane endpoint (<150 days of age) for untreated SD mice using LC-MS/MS mass spectrometry. Treatment groups were compared to untreated SD mice using two-way ANOVA with Dunnett’s multiple comparison test for each tissue: ∗∗p < 0.01; ∗∗∗∗p < 0.0001.